These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19171407)

  • 1. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.
    Luciani A; Bertuzzi C; Ascione G; Di Gennaro E; Bozzoni S; Zonato S; Ferrari D; Foa P
    Lung Cancer; 2009 Oct; 66(1):94-6. PubMed ID: 19171407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do elderly cancer patients achieve an adequate dose intensity in common clinical practice?
    Luciani A; Marussi D; Ascione G; Caldiera S; Ferrari D; Oldani S; Uziel L; Zonato S; Foa P
    Oncology; 2006; 71(5-6):382-7. PubMed ID: 17851263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
    J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer.
    O'Brien ME; Yau T; Coward J; Hughes S; Papadopoulos P; Popat S; Norton A; Ashley S
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):142-7. PubMed ID: 18093813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
    Grossi F; Aita M; Defferrari C; Rosetti F; Brianti A; Fasola G; Vinante O; Pronzato P; Pappagallo G
    Oncologist; 2009 May; 14(5):497-510. PubMed ID: 19423674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States.
    Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Morissette N; Thompson D
    Lung Cancer; 2009 Feb; 63(2):264-70. PubMed ID: 18649969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).
    Honecker F; Wedding U; Bokemeyer C;
    Onkologie; 2004 Dec; 27(6):583-8. PubMed ID: 15591721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer.
    d'Amato TA; Ashrafi AS; Schuchert MJ; Alshehab DS; Seely AJ; Shamji FM; Maziak DE; Sundaresan SR; Ferson PF; Luketich JD; Landreneau RJ
    Ann Thorac Surg; 2009 Oct; 88(4):1079-85. PubMed ID: 19766784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options for elderly patients with advanced non-small cell lung cancer.
    Avery EJ; Kessinger A; Ganti AK
    Cancer Treat Rev; 2009 Jun; 35(4):340-4. PubMed ID: 19155139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
    Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.